


The '591 PCT application does not disclose asymmetric polymeric coatings. The '059 and '220 patents, while disclosing asymmetric polymeric coatings, do not disclose the suitability of controlled-release compositions comprising such asymmetric coatings for administration to a high-fat use-environment.

Date: 6/26/07

Respectfully submitted,

By: 
Robert M. Kennedy
Attorney for Applicant(s)
Reg. No. 28,026

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5303

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
IN RE APPLICATION OF: Mark B. Chidlaw, et al :

APPLICATION NO.: 10/727,217 : **Examiner:** Tran, Susan T.
FILING DATE: December 3, 2003 : **Group Art Unit:** 1615
TITLE: CONTROLLED-RELEASE OF AN ACTIVE :
SUBSTANCE INTO A HIGH FAT
ENVIRONMENT

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 C.F.R. 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees, which may be required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: June 26, 2007

/ Robert M. Kennedy /
Robert M. Kennedy
Attorney for Applicant(s)
Reg. No. 28,026

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5303

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC9858A				SERIAL NO. 10/727,217			
				APPLICANT Mark B. Chidiaw, et al.							
				FILING DATE December 3, 2003				GROUP 1614			

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE if appropriate	

FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>													
		1. The International Preliminary Examination Report for WO2004/052343 which corresponds to the present application.											
		2. The Written Opinion prepared by the Australian Patent Office for the Singapore Patent Office for the Singapore patent application corresponding to the present application.											
		3. Examination Report prepared by the Australian Patent Office for the Singapore Patent Office for the Singapore patent application corresponding to the present application.											

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.